|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM276399056 |
| 003 |
DE-627 |
| 005 |
20231225011923.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2017 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2017.09.022
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0921.xml
|
| 035 |
|
|
|a (DE-627)NLM276399056
|
| 035 |
|
|
|a (NLM)28970186
|
| 035 |
|
|
|a (PII)S1521-6616(17)30212-7
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Gao, Chen
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Vaccination with a recombinant OprL fragment induces a Th17 response and confers serotype-independent protection against Pseudomonas aeruginosa infection in mice
|
| 264 |
|
1 |
|c 2017
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 13.12.2017
|
| 500 |
|
|
|a Date Revised 09.12.2020
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2017 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Pseudomonas aeruginosa (PA) is the major causative agent of nosocomial infection. Despite of adequate use of antibiotics, it still represents a major challenge in controlling PA infection. The local pulmonary Th17 response plays an important protective role against PA infection. And the Th17-mediated protection is antibody independent, so we hypothesized that it would be an optimal strategy of a vaccine for PA control to induce an effective Th17 response. Herein we report the successful production of a recombinant fragment of the OprL (reOprL) of PA. Purified reOprL forms homogeneous monomers in solution and vaccination with reOprL elicited a remarkable Th17 response. In addition, reOprL vaccination conferred effective serotype-independent protection against PA infection, which relied on the Th17 response. Our data suggest that reOprL is a good candidate for the future development of Th17 immunity based PA vaccines
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a OprL
|
| 650 |
|
4 |
|a Pseudomonas Aeruginosa
|
| 650 |
|
4 |
|a Th17
|
| 650 |
|
4 |
|a Vaccine
|
| 650 |
|
7 |
|a Bacterial Proteins
|2 NLM
|
| 650 |
|
7 |
|a Bacterial Vaccines
|2 NLM
|
| 700 |
1 |
|
|a Yang, Feng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Ying
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liao, Yaling
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Jinyong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zeng, Hao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zou, Quanming
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gu, Jiang
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 183(2017) vom: 01. Okt., Seite 354-363
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:183
|g year:2017
|g day:01
|g month:10
|g pages:354-363
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2017.09.022
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 183
|j 2017
|b 01
|c 10
|h 354-363
|